GlassScriptPhysician profile
Philip Woodham
NPI 1174667836
$13,492.97
in general payments reported to CMS, 2019-2025
25 companies · $1,077 in 2025
The $1,077 reported for 2025 was more than what 86% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $8,589 · 2020: $512 · 2021: $432 · 2022: $883 · 2023: $933 · 2024: $1,067 · 2025: $1,077.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,912 · Travel and Lodging: $149 · Education: $16.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.62 |
| Travel and Lodging | $149.17 |
| Education | $16.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $10,620.61 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Sanofi-Aventis U.S. LLC | $791.78 | 2019-2025 | |
| Abbott Laboratories | $422.85 | 2022-2024 | Freestyle Libre 3, Freestyle Libre |
| Glaxosmithkline, LLC. | $407.92 | 2023-2025 | Shingrix, Arexvy |
| Lilly USA, LLC | $335.57 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $130.95 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $119.62 | 2024-2025 | |
| Amgen INC. | $104.33 | 2019-2025 | Uplizna, Tavneos, Repatha |
| Exact Sciences Corporation | $91.00 | 2024-2025 | Cologuard Collection Kit |
| Dynavax Technologies Corporation | $85.04 | 2023-2024 | Heplisav-B |
| Boehringer Ingelheim Pharmaceuticals, INC. | $60.93 | 2019-2025 | Jardiance, Synjardy |
| Corcept Therapeutics | $38.92 | 2025 | Korlym |
| Insightec,INC | $36.38 | 2025 | Exablate |
| Cycle Pharmaceuticals INC | $31.12 | 2024 | Tiopronin |
| Pfizer INC. | $29.08 | 2019-2024 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $29.04 | 2024-2025 | Farxiga |
| Alexion Pharmaceuticals, INC. | $24.44 | 2024 | Ultomiris |
| Gilead Sciences, INC. | $22.79 | 2023 | Epclusa |
| Dexcom, INC. | $19.95 | 2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $17.28 | 2025 | Veozah |
| Kyowa Kirin, INC. | $16.15 | 2024 | Crysvita |
| Inspire Medical Systems, INC. | $15.78 | 2025 | Inspire |
| Xeris Pharmaceuticals, INC. | $14.35 | 2023 | Keveyis |
| Abbvie INC. | $14.00 | 2020 | |
| Sanofi Pasteur INC. | $13.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Woodham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.